A 58-year-old man from Mumbai presents with progressive dyspnea, orthopnea, and lower limb edema for 6 months. Echocardiography shows restrictive cardiomyopathy with biopsy-proven cardiac amyloidosis (Congo red positive with apple-green birefringence). Serum and urine protein electrophoresis are normal. Cardiac MRI shows diffuse late gadolinium enhancement. What is the most appropriate next step in management?

Explanation

## Diagnostic Approach to Amyloidosis **Key Point:** Once amyloidosis is histologically confirmed (Congo red staining), the critical next step is **amyloid typing** — determining whether it is AL (light-chain), AA (serum amyloid A), or hereditary (e.g., ATTRwt, ATTRm). This distinction drives all subsequent management decisions. ### Why Typing is Essential | Amyloid Type | Pathophysiology | First-Line Treatment | Prognosis | |---|---|---|---| | AL (Light-chain) | Misfolded immunoglobulin light chains (κ or λ) | Proteasome inhibitors ± chemotherapy | Median survival ~4 years untreated | | AA (Reactive) | Serum amyloid A from chronic inflammation | Treat underlying disease (TB, rheumatoid arthritis, FMF) | Variable; depends on control of primary disease | | ATTRwt (Wild-type) | Mutant transthyretin (age-related) | Tafamidis, diflunisal, or supportive care | Slowly progressive; median survival ~10 years | | ATTRm (Hereditary) | Mutant transthyretin (inherited) | Tafamidis, inotersen, or liver transplant | Rapidly progressive if untreated | **Clinical Pearl:** In this case, normal serum and urine protein electrophoresis make AL amyloidosis less likely but do not exclude it (free light chains may be present without M-spike). Mass spectrometry or immunohistochemistry on the biopsy specimen is the gold standard for definitive typing. **High-Yield:** The amyloid type determines: - Whether chemotherapy is indicated (AL only) - Whether the underlying disease requires treatment (AA) - Whether genetic counseling and family screening are needed (hereditary ATTR) - Prognosis and eligibility for emerging therapies (tafamidis for ATTR, lenalidomide for AL) ### Why Other Options Are Premature - **Chemotherapy without typing:** Bortezomib is effective for AL amyloidosis but harmful or ineffective in AA or ATTR. Initiating chemotherapy blindly risks toxicity in a patient who may not have AL. - **Symptomatic management alone:** While diuretics and ACE inhibitors provide symptomatic relief, they do not address the underlying amyloid burden and are insufficient monotherapy without disease-specific treatment. - **Immediate heart transplantation:** Transplant is reserved for end-stage disease unresponsive to medical therapy or for select AL patients after chemotherapy-induced remission. It is not a first-line step. **Mnemonic: ATTIC** — **A**myloid typing, **T**hen **T**arget therapy, **I**nvestigate cause, **C**ontrol symptoms. ## Practical Next Steps After Typing ```mermaid flowchart TD A[Cardiac biopsy: Congo red positive]:::outcome --> B[Perform mass spectrometry or immunohistochemistry]:::action B --> C{Amyloid type identified?}:::decision C -->|AL light-chain| D[Serum/urine free light chains, bone marrow biopsy, hematology referral]:::action C -->|AA reactive| E[Investigate and treat underlying chronic disease]:::action C -->|ATTR hereditary| F[Genetic testing, family screening, cardiology + neurology referral]:::action C -->|ATTR wild-type| G[Tafamidis or supportive care, cardiology follow-up]:::action D --> H[Chemotherapy ± stem cell transplant if AL confirmed]:::action E --> I[NSAIDs, colchicine, or biologic therapy as indicated]:::action F --> J[Tafamidis, inotersen, or liver transplant consideration]:::action ``` [cite:Robbins 10e Ch 6]